0
Other Articles |

ELIXIR OF SULFANILAMIDE-MASSENGILL: II

JAMA. 1937;109(21):1724-1725. doi:10.1001/jama.1937.92780470007014.
Text Size: A A A
Published online

ABSTRACT

The report on the Elixir of Sulfanilamide-Massengill episode published in the November 6 issue of The Journal, pages 1531-1539, contained a survey map of the deaths to October 29. Herewith the survey map is brought down to date. This shows that there have been seventy-three deaths reported to November 11. As may be seen, all but a few of the reported deaths have been from the Southern states. It is emphasized that the additional deaths reported are not recent but have only recently been reported as having followed the administration of Elixir of Sulfanilamide-Massengill. That no recent deaths have occurred shows the effect of the wide publicity initiated by The Journal and the excellent work of the government in removing the product from the market.

In reports appearing in the newspapers and elsewhere there has been considerable confusion; many of the deaths have been attributed to sulfanilamide, which was not the causative factor. As pointed out previously, the diethylene glycol used in the solvent was the harmful agent. There has been further confusion between the various sulfanilamide derivatives, their properties and names, and the chemical difference between ethylene glycol and diethylene glycol. For the information of physicians there is reproduced herewith a chart, modified from that shown at the last annual session of the American Medical

Topics

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

References

CME
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs